ISRCTN10521680 https://doi.org/10.1186/ISRCTN10521680

Phase I trial, Quotient code: QSC205601

Submission date 31/01/2022	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol
Registration date 01/02/2022	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 18/02/2026	**Condition category** Other	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Dr Stuart Mair

Contact details
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)1159749000
recruitment@weneedyou.co.uk

Type(s)
Scientific, Public

Contact name
None - Novartis Study Director

Contact details
Lichtstrasse 35
Basel
Switzerland

4056
+41 61 324 11 11
novartis.email@novartis.com

Additional identifiers

Clinical Trials Information System (CTIS)
2021-000600-38

Integrated Research Application System (IRAS)
304054

Protocol serial number
Quotient code: QSC205601

Study information

Scientific Title
Phase I trial, Quotient code: QSC205601 [The full scientific title will be published within 30 months after the end of the trial]

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Ethics approval required
Old ethics approval format

Ethics approval(s)
1. Approved 24/11/2021, London Bridge Research Ethics Committee (London HRA Centre, 2nd Floor, 2 Redman Place, Stratford, London, E20 1JQ, UK; +44 (0)207 1048202, +44 (0)207 1048124; londonbridge.rec@hra.nhs.uk), REC ref: 21/LO/0761
2. Approved 31/12/2021, MHRA (10 South Colonnade, Canary Wharf, London E14 4PU, UK; +44 (0)20 3080 6000; info@nhra.gov.uk), ref: CTA 04935/0192/001-0001
The HRA has approved deferral of publication of trial details.

Study design
Phase I trial to assess safety, tolerability and pharmacokinetics in 116 healthy volunteers

Primary study design
Other

Study type(s)
Other

Health condition(s) or problem(s) studied
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Key secondary outcome(s))
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Completion date
06/10/2022

Eligibility

Key inclusion criteria
Healthy human volunteer

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
101

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Date of first enrolment
02/02/2022

Date of final enrolment
06/10/2022

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences
Trent House
Mere Way
Ruddington Fields Business Park
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Novartis (Switzerland)

ROR
https://ror.org/02f9zrr09

Funder(s)

Funder type
Industry

Funder Name
Novartis Pharma AG

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			26/07/2023	No	No